Cerevel Therapeutics Holdings, Inc.
CERE
Kedudukan dalam Saham
#2810
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Harga Saham
$44.96
Disegerakkan terakhir: 2024-08-01
Modal Pasaran
$6.67B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Cerevel Therapeutics Holdings, Inc. (CERE)
Kategori
Healthcare
Nisbah P/E bagi Cerevel Therapeutics Holdings, Inc. (CERE)
Nisbah P/E pada October 2026 TTM: -16.84
Menurut laporan kewangan dan harga saham terkini Cerevel Therapeutics Holdings, Inc., nisbah P/E semasa (TTM) ialah -16.84. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -13.57.
Sejarah nisbah P/E bagi Cerevel Therapeutics Holdings, Inc. dari 2012 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -16.84 | 6.11% |
| 2023 | -15.87 | 16.96% |
| 2022 | -13.57 | -31.81% |
| 2021 | -19.91 | 54.55% |
| 2020 | -12.88 | 9.30% |
| 2019 | -11.78 | 549.47% |
| 2018 | -1.81 | -69.85% |
| 2015 | -6.02 | 4.14% |
| 2014 | -5.78 | 10.88% |
| 2013 | -5.21 | -9.54% |
| 2012 | -5.76 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -270.92% |
US
|
|
| -28.36 | 68.41% |
US
|
|
| -24.57 | 45.89% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -280.12% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.